Literature DB >> 1824264

Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice.

J B Porter1, K P Hoyes, R D Abeysinghe, P N Brooks, E R Huehns, R C Hider.   

Abstract

Five orally effective iron chelators of the 3-hydroxypyridin-4-one series have been administered intraperitoneally to iron-overloaded and nonoverloaded male mice at a dose of 200 mg/kg/24 h for a total of 60 days to investigate the effect on iron loading and toxicity. There was a significant reduction in hepatic iron at the end of the study in the iron-overloaded mice with all compounds studied using chemical iron quantitation (P less than .001) and with Perls' stain (P less than .01). Liver iron removal with the hydroxypyridinones ranged from 37% with CP20 to 63% with CP51, compared with 46% removal for desferrioxamine (DFO). There was no significant reduction in splenic or cardiac iron with any chelator. There were no deaths in iron-overloaded animals receiving any of the hydroxypyridin-4-ones, but significantly more deaths in the nonoverloaded groups as a whole (P less than .03). No weight loss was observed with any chelator. Significant reductions in hemoglobin and white cell count were observed with CP20(L1). No histologic abnormalities of kidney, spleen, bone marrow, or stifle joints were observed. Intracytoplasmic inclusion bodies were observed in the centrilobular hepatocytes of animals administered each of the hydroxypyridin-4-ones, while the DFO-treated and control groups showed no such changes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824264

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

Authors:  N Lowther; R Fox; B Faller; H Nick; Y Jin; T Sergejew; Y Hirschberg; R Oberle; H Donnelly
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

Review 2.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

3.  Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti; Shailendra Singh
Journal:  J Med Chem       Date:  2008-06-06       Impact factor: 7.446

4.  Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes.

Authors:  R D Abeysinghe; B L Ellis; J B Porter
Journal:  Eur J Nucl Med       Date:  1994-10

5.  Site-specific intestinal DMT1 silencing to mitigate iron absorption using pH-sensitive multi-compartmental nanoparticulate oral delivery system.

Authors:  Yingfang Fan; Harkiranpreet Kaur Dhaliwal; Archita Venugopal Menon; JuOae Chang; Jee Eun Choi; Mansoor M Amiji; Jonghan Kim
Journal:  Nanomedicine       Date:  2019-10-15       Impact factor: 5.307

Review 6.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228

7.  Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.

Authors:  Alison Curnow; Alexis Perry; Mark Wood
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-12-13       Impact factor: 3.631

8.  A study on the analgesic effects of four new derivatives of 3-hydroxy pyridine-4-one.

Authors:  V Hajhashemi; L Saghaei; A Fassihi; H Mojiri-Froshani
Journal:  Res Pharm Sci       Date:  2012-01

9.  Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis.

Authors:  Chhanda Bose; Judit K Megyesi; Sudhir V Shah; Kim M Hiatt; Kimberly A Hall; Oleg Karaduta; Sundararaman Swaminathan
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

10.  Effect of Systemic Iron Overload and a Chelation Therapy in a Mouse Model of the Neurodegenerative Disease Hereditary Ferritinopathy.

Authors:  Holly J Garringer; Jose M Irimia; Wei Li; Charles B Goodwin; Briana Richine; Anthony Acton; Rebecca J Chan; Munro Peacock; Barry B Muhoberac; Bernardino Ghetti; Ruben Vidal
Journal:  PLoS One       Date:  2016-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.